Daina Graybosch, an analyst from Leerink Partners, reiterated the Buy rating on 2seventy bio (TSVT – Research Report). The associated ...

(TSVT) stock lost as company with Bristol Myers Squibb (BMY) plan to discontinue enrollments in a Phase 3 trial for cancer ...

据了解，2seventy bio和其合作伙伴百时美施贵宝宣布，将停止新诊断的多发性骨髓瘤患者使用的T细胞免疫疗法Abecma的III期临床试验。这项名为KarMMa-9的研究，旨在评估Abecma与来那度胺联合治疗，以及来那度胺单药治疗的效果。两家公司表示，这一决定是在对该研究的商业理由进行彻底审查后做出的。

Bristol Myers Squibb’s struggling CAR-T therapy Abecma has hit a major setback. | Bristol Myers Squibb’s CAR-T therapy Abecma ...

据研究报告，在接受 CAR-T 细胞治疗之前，患者接受过中位数超过三种疗法的 SPM 风险明显高于之前接受过少于三种疗法的患者。同样，在随访时间低于中位数 21.7 个月的研究中，SPM 的发生率为 ...

KarMMa-9 trial for Abecma, saving $80 million and focusing on profitability by 2025. Despite the decision, the company ...

Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of ...

据了解，2seventy ...

TSVT announced that it will discontinue enrollment in its ongoing phase III KarMMa-9 study.The study is evaluating Abecma ...

Bristol Myers Squibb, 2seventy bio to discontinue enrollment in phase 3 KarMMa-9 study of Abecma in patients with newly diagnosed MM: Princeton, New Jersey Friday, September 27, 2 ...

Inc. (Nasdaq: TSVT) today announced that the Company, in partnership with study sponsor Bristol Myers Squibb (BMS), will ...

通过建立《再生医学促进法》《再生医学安全法》等特殊法规监管途径，十多年来，日本不遗余力地鼓励细胞疗法的开发和商业化，批准了许多产品。它们大部分是由日本公司推出的，但也包括来自欧美MNC的CAR-T疗法。